🔴 Pyxis Oncology is trading 5.66% down in pre-market after a wider-than-expected second-quarter loss

Pyxis Oncology is trading 5.66% down at $3.00 after reporting a second-quarter 2026 loss of $0.40 per share versus the expected $0.34.

• The company reported no milestone revenue.
• Cash runway was extended into the second quarter of 2027.
• Shares gained 12.37% on August 12 and fell 26.11% on August 11; broader markets were nearly flat.